Physician profile
Nakul Singhal
NPI 1366733156
$1,773.13
in general payments reported to CMS, 2019-2025
38 companies · $540 in 2025
The $540 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $138 · 2021: $153 · 2022: $202 · 2023: $224 · 2024: $353 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,026 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,026.46 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $252.86 | 2024-2025 | Illuccix |
| Astellas Pharma US INC | $146.79 | 2019-2025 | Padcev |
| Kite Pharma, INC. | $139.97 | 2020-2022 | |
| Celgene Corporation | $111.20 | 2022-2023 | Reblozyl |
| Pfizer INC. | $87.05 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $84.66 | 2019-2025 | |
| Abbvie INC. | $84.17 | 2023 | Qulipta, Venclexta |
| E.R. Squibb & Sons, L.L.C. | $66.13 | 2019-2023 | Opdivo |
| Janssen Biotech, INC. | $61.37 | 2021-2025 | Rybrevant |
| Rigel Pharmaceuticals, INC. | $56.32 | 2023-2024 | Tavalisse, Rezlidhia |
| Glaxosmithkline, LLC. | $56.05 | 2021-2023 | Zejula |
| Beone Medicines USA, INC. | $53.65 | 2025 | Brukinsa |
| Genzyme Corporation | $53.60 | 2024 | |
| Genentech USA, INC. | $36.58 | 2019-2025 | Venclexta |
| Teva Pharmaceuticals USA, INC. | $28.58 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $28.53 | 2024 | Ogsiveo |
| Recordati_rare_diseases_inc. | $28.10 | 2025 | Enjaymo |
| Tactile Systems Technology INC | $27.63 | 2022 | |
| Amgen INC. | $27.53 | 2021 | |
| Incyte Corporation | $24.98 | 2025 | Jakafi |
| G1 Therapeutics, INC. | $23.89 | 2023 | Cosela |
| Global Blood Therapeutics, INC. | $22.68 | 2020 | |
| Daiichi Sankyo INC. | $22.50 | 2025 | Vanflyta |
| Lundbeck LLC | $21.71 | 2025 | Vyepti |
| Puma Biotechnology, INC. | $21.62 | 2024 | |
| Aurinia Pharma U.S., INC. | $19.91 | 2025 | Lupkynis |
| Mylan Institutional INC. | $19.84 | 2020 | |
| Merck Sharp & Dohme LLC | $18.53 | 2020 | |
| Sobi, INC | $18.22 | 2025 | |
| Dova Pharmaceuticals | $16.28 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $15.67 | 2025 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $14.93 | 2019 | |
| Lilly USA, LLC | $14.79 | 2019 | |
| Mirati Therapeutics, INC. | $14.79 | 2023 | Krazati |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.35 | 2019 | |
| Secura Bio, INC. | $13.04 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.71 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nakul Singhal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.